Your browser is no longer supported. Please, upgrade your browser.
BMRN BioMarin Pharmaceutical Inc. monthly Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-1.02 Insider Own0.50% Shs Outstand175.29M Perf Week-6.65%
Market Cap15.53B Forward P/E- EPS next Y-0.25 Insider Trans-15.00% Shs Float174.61M Perf Month-3.78%
Income-174.60M PEG- EPS next Q-0.11 Inst Own- Short Float5.13% Perf Quarter1.00%
Sales1.20B P/S12.93 EPS this Y-253.70% Inst Trans0.02% Short Ratio6.85 Perf Half Y-1.78%
Book/sh16.03 P/B5.53 EPS next Y65.30% ROA-4.40% Target Price112.45 Perf Year3.77%
Cash/sh4.15 P/C21.34 EPS next 5Y25.00% ROE-6.40% 52W Range78.42 - 100.51 Perf YTD6.98%
Dividend- P/FCF- EPS past 5Y-51.20% ROI-17.50% 52W High-12.72% Beta1.80
Dividend %- Quick Ratio2.70 Sales past 5Y20.40% Gross Margin81.60% 52W Low11.87% ATR2.29
Employees2293 Current Ratio3.90 Sales Q/Q5.80% Oper. Margin-17.40% RSI (14)33.93 Volatility3.49% 2.34%
OptionableYes Debt/Eq0.24 EPS Q/Q91.80% Profit Margin-14.50% Rel Volume1.41 Prev Close88.62
ShortableYes LT Debt/Eq0.24 EarningsOct 26 AMC Payout- Avg Volume1.31M Price87.73
Recom1.90 SMA20-6.44% SMA50-1.95% SMA200-2.25% Volume752,459 Change-1.00%
Oct-06-17Resumed Goldman Buy $129
Sep-15-17Initiated RBC Capital Mkts Sector Perform $93
Sep-14-17Initiated Piper Jaffray Overweight $113
Aug-31-17Initiated Citigroup Buy $98
Aug-17-17Initiated Evercore ISI Outperform $100
Mar-30-17Initiated UBS Neutral $92
Mar-02-17Initiated Instinet Neutral $93
Feb-07-17Initiated Morgan Stanley Overweight $110
Jan-23-17Resumed Credit Suisse Outperform
Dec-08-16Initiated Gabelli & Co Buy $109
Nov-07-16Downgrade Piper Jaffray Overweight → Neutral
Nov-03-16Initiated Deutsche Bank Buy $106
Aug-05-16Reiterated Stifel Buy $107 → $113
Aug-05-16Reiterated Piper Jaffray Overweight $107 → $120
Mar-08-16Upgrade Robert W. Baird Neutral → Outperform $110
Mar-03-16Reiterated Stifel Buy $105 → $107
Feb-29-16Reiterated Wedbush Neutral $117 → $105
Feb-26-16Reiterated RBC Capital Mkts Outperform $155 → $125
Feb-16-16Upgrade Stifel Hold → Buy $105
Jan-20-16Initiated Credit Suisse Outperform
Oct-19-17 09:00AM  Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi Zacks
08:16AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : October 19, 2017 Capital Cube
06:39AM  BioMarin Pharmaceutical: Cramer's Top Takeaways TheStreet.com
Oct-18-17 07:00PM  BioMarin is 'close as can get' to a hemophilia cure, CEO ... CNBC Videos -5.26%
02:11PM  Have Investors Already Priced In BioMarin Pharmaceutical Incs (BMRN) Growth? Simply Wall St.
12:24PM  BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York PR Newswire
08:05AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Oct-16-17 01:07PM  BioMarin Pharmaceutical, Inc. (Nasdaq: BMRN) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Oct-13-17 12:09PM  How Spark's Gene Therapy Win Could Also Be A Boon For These Biotechs Investor's Business Daily
Oct-11-17 08:30AM  BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York PR Newswire
Oct-10-17 08:30AM  BioMarin to Host Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, October 26 at 4:30 p.m. ET PR Newswire
Oct-09-17 08:02AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
07:43AM  Analysts Recommendations for Biogen in October 2017 Market Realist
Oct-04-17 07:44AM  Alexion on the Street: Analyst Recommendations in October Market Realist
Oct-03-17 08:30AM  BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors PR Newswire
Oct-02-17 08:04AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Sep-29-17 08:02AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Sep-28-17 08:02AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Sep-27-17 10:24AM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : September 27, 2017 Capital Cube
Sep-25-17 09:40AM  Here's Why Sarepta Stock is Up More Than 60% So Far in 2017 Zacks
Sep-20-17 08:45AM  Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook Zacks
Sep-18-17 05:37PM  BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA Zacks
09:00AM  Billionaire George Soros' Fund Bought These 3 Pharma Stocks: Should You? Motley Fool
Sep-14-17 04:05PM  FDA Not Currently Planning to Hold Advisory Committee Meeting for BioMarin's Pegvaliase Biologics License Application (BLA) PR Newswire
Sep-13-17 05:33PM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : September 13, 2017 Capital Cube
Sep-12-17 08:06AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
07:37AM  BioMarins Strong Pipeline Could Be a Long-Term Growth Driver Market Realist
Sep-11-17 02:16PM  BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 Capital Cube
10:37AM  How Did BioMarin Pharmaceuticals Drugs Perform in 1H17? Market Realist
09:07AM  How Did BioMarin Pharmaceuticals Perform in 2Q17? Market Realist
07:38AM  What Analysts Recommend for BioMarin Pharmaceuticals in September Market Realist
Sep-07-17 01:24PM  BioMarin Presents Interim Data on BMN 250 from Phase I/II Zacks
04:32AM  BioMarin (BMRN) Up 2.5% Since Earnings Report: Can It Continue? Zacks
Sep-06-17 11:00AM  BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at 13th International Congress of Inborn Errors of Metabolism (ICIEM) 2017 PR Newswire
07:37AM  Behind Bioverativs Analyst Recommendations This September Market Realist
Sep-05-17 10:53PM  BioMarin Pharmaceutical, Inc. Value Analysis (NASDAQ:BMRN) : September 6, 2017 Capital Cube
12:31PM  Sarepta: Time to Buy? Barrons.com
11:50AM  Alexion: Quite a Comeback Barrons.com
08:30AM  BioMarin Announces 3 Platform and 15 Poster Presentations at 13th International Congress of Inborn Errors of Metabolism 2017 PR Newswire
Aug-31-17 01:50PM  Biotech ETF on track for fourth straight daily rise, hits highest level since 2015 MarketWatch
09:00AM  BioMarin (BMRN) in Focus: Stock Moves 5.6% Higher Zacks
08:54AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : August 31, 2017 Capital Cube
08:42AM  Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update Zacks
Aug-30-17 04:23PM  How Much Can This Biotech Pop After The FDA OKs Its Drug Bid? Investor's Business Daily +5.63%
03:01PM  Why BioMarin is Jumping Barrons.com
11:10AM  BioMarin's Pegvaliase BLA Granted Priority Review by the FDA Zacks
Aug-29-17 04:05PM  FDA Accepts BioMarin's Pegvaliase Biologics License Application (BLA) and Grants Priority Review Designation PR Newswire
10:00AM  These 3 Stocks Look Expensive but Are Actually Cheap Motley Fool
Aug-23-17 04:05PM  BioMarin Announces Exercise in Full of Underwriters' Option to Purchase Additional 0.599% Senior Subordinated Convertible Notes Due 2024 PR Newswire
11:38AM  3 Big Stock Charts for Wednesday: Twilio Inc (TWLO), BioMarin Pharmaceutical Inc. (BMRN) and Mondelez International Inc (MDLZ) InvestorPlace
Aug-21-17 08:30AM  Forbes Ranks BioMarin 12th Most Innovative Company in the World PR Newswire
Aug-17-17 10:05AM  Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst TheStreet.com
Aug-15-17 04:22PM  Why Gilead Sciences Might Not Make an Oncology Acquisition Motley Fool
08:30AM  BioMarin to Attend Upcoming Investor Conferences PR Newswire
Aug-12-17 08:02AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Aug-11-17 09:26PM  Edited Transcript of BMRN earnings conference call or presentation 2-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
08:02AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Aug-10-17 08:02AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Aug-09-17 08:02AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
06:00AM  20 Undervalued, Sustainable Stocks Morningstar
Aug-08-17 10:17AM  What Weighed On Biotechs Last Week? Barrons.com
Aug-07-17 07:24PM  BioMarin Announces Offering of $450 Million of 0.599% Senior Subordinated Convertible Notes Due 2024 PR Newswire
04:01PM  BioMarin Announces Offering of $450 Million of Senior Subordinated Convertible Notes Due 2024 PR Newswire
Aug-04-17 01:43PM  BioMarin Pharmaceutical Inc. Got It Done in the Second Quarter Motley Fool
Aug-03-17 09:38AM  BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates Zacks
Aug-02-17 10:02PM  BioMarin reports 2Q loss Associated Press
04:05PM  BioMarin Announces Second Quarter 2017 Financial Results PR Newswire
04:01PM  BioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therapy for Hemophilia A, into Phase 3 Studies PR Newswire
10:20AM  Investor Network: BioMarin Pharmaceutical Inc. to Host Earnings Call ACCESSWIRE
Jul-31-17 04:01PM  BioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET PR Newswire
09:34AM  Will Teladoc (TDOC) Pull Off a Surprise in Q2 Earnings? Zacks
08:41AM  Why Earnings Season Could Be Great for BioMarin (BMRN) Zacks
Jul-27-17 09:03AM  Can BioMarin (BMRN) Keep the Earnings Streak Alive in Q2? Zacks
Jul-24-17 02:27PM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : July 24, 2017 Capital Cube
Jul-20-17 01:09PM  Sarepta Therapeutics (SRPT) Stock Surged 24% Today: Here's Why Zacks
Jul-19-17 04:56PM  Sarepta & BioMarin Settle Patent Litigation on Exon Skipping Zacks
04:22PM  Sarepta Rockets On Consensus-Crushing Sales, Narrowing Losses Investor's Business Daily
01:45PM  Sarepta skips over a Duchenne patent battle with $35M settlement American City Business Journals
08:39AM  Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs Zacks
Jul-18-17 04:30PM  BioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET PR Newswire
01:45PM  BioMarin snags cash as Sarepta skips Duchenne patent battle American City Business Journals
01:32PM  Sarepta, BioMarin Fall After Settling Patent Fight Barrons.com
08:30AM  Sarepta Therapeutics and BioMarin Pharmaceutical Inc. Announce Execution of a Global Settlement and a License Agreement Resolving Exon Skipping Patent Litigation GlobeNewswire
Jul-14-17 01:09PM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : July 14, 2017 Capital Cube
Jul-13-17 09:46AM  Biotech 2Q17: It's Mostly all Gravy Barrons.com
Jul-12-17 08:34AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : July 12, 2017 Capital Cube
Jul-11-17 04:43PM  Could This Biotech Win In Hemophilia With 'One And Done' Drug? Investor's Business Daily
03:30AM  BioMarin's Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg Dose Maintains Average Factor VIII Levels within Normal Range for over One Year PR Newswire
Jul-10-17 09:07AM  What Analysts Recommend for BioMarin Pharmaceuticals Market Realist
07:38AM  BioMarin Expects These Drugs to Generate Steady Revenues Market Realist
Jul-07-17 05:08PM  A Barrage Of Biotech Updates Expected At ISTH Meeting Benzinga
04:37PM  Vimizim Could Significantly Drive BioMarins Revenue Growth Market Realist
03:05PM  Kuvan Could Boost BioMarins Revenue Growth in 2017 Market Realist
01:30PM  What to Expect from BioMarin Pharmaceuticals in 2017 Market Realist
Jul-05-17 08:12AM  Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More Zacks
Jul-03-17 10:11AM  BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase Zacks
Jun-30-17 09:10AM  BioMarin Submits Pegvaliase Biologics License Application (BLA) to the U.S. FDA for Treatment of Phenylketonuria (PKU) PR Newswire
Jun-28-17 09:08AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : June 28, 2017 Capital Cube
Jun-27-17 02:36PM  Rare Diseases: Biotech's High Risk, Highest Reward Sub-Sector Forbes
Jun-26-17 03:27PM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : June 26, 2017 Capital Cube
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAFFI ROBERTEVP, Technical OperationsSep 28Sale92.062,915268,35528,761Oct 02 09:07 PM
BAFFI ROBERTEVP, Technical OperationsSep 28Sale92.5015,5001,433,676129,083Oct 02 09:07 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerSep 22Option Exercise37.463,521131,89750,110Sep 26 07:19 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerSep 22Sale95.003,521334,49547,944Sep 26 07:19 PM
FUCHS HENRY JPresident, Worldwide R&DSep 15Option Exercise33.8015,000507,050151,422Sep 19 03:17 PM
LAWLIS V BRYANDirectorSep 15Option Exercise38.593,750144,71319,660Sep 19 03:27 PM
FUCHS HENRY JPresident, Worldwide R&DSep 15Sale90.5015,0001,357,500136,422Sep 19 03:17 PM
LAWLIS V BRYANDirectorSep 15Sale91.263,750342,22515,910Sep 19 03:27 PM
Davis George EricEVP, General CounselJun 23Option Exercise38.599,844379,88093,425Jun 27 08:46 PM
Davis George EricEVP, General CounselJun 23Sale96.609,844950,93083,581Jun 27 08:46 PM
Mueller BrianSVP, Corporate ControllerJun 22Option Exercise21.512,67157,45315,556Jun 23 05:39 PM
Mueller BrianSVP, Corporate ControllerJun 22Sale100.002,671267,10012,885Jun 23 05:39 PM
FUCHS HENRY JPresident, Worldwide R&DJun 19Option Exercise37.4660322,588137,025Jun 20 06:33 PM
FUCHS HENRY JPresident, Worldwide R&DJun 19Sale90.0060354,270136,422Jun 20 06:33 PM
LAWLIS V BRYANDirectorJun 16Option Exercise38.593,750144,71319,660Jun 20 06:31 PM
FUCHS HENRY JPresident, Worldwide R&DJun 16Option Exercise33.6514,397484,462150,819Jun 20 06:33 PM
FUCHS HENRY JPresident, Worldwide R&DJun 16Sale90.0014,3971,295,730136,422Jun 20 06:33 PM
LAWLIS V BRYANDirectorJun 16Sale90.003,750337,50015,910Jun 20 06:31 PM
Davis George EricEVP, General CounselJun 09Option Exercise23.549,239217,53083,581Jun 13 08:56 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerJun 07Sale89.611,00489,96847,944Jun 09 06:31 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 05Option Exercise17.335,00086,650231,924Jun 06 08:34 PM
Davis George EricEVP, General CounselJun 05Sale91.049,471862,23074,342Jun 07 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 05Sale90.565,000452,800226,924Jun 06 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 02Option Exercise17.335,00086,650238,564Jun 06 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 02Sale89.705,000448,500233,564Jun 06 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 01Option Exercise17.335,00086,650238,564Jun 05 07:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 01Sale87.535,000437,650233,564Jun 05 07:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 31Option Exercise17.337,423128,641240,987Jun 02 05:52 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 31Sale88.297,423655,377233,564Jun 02 05:52 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 24Option Exercise17.335,00086,650238,564May 26 05:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 24Sale88.385,000441,900233,564May 26 05:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 17Option Exercise17.335,00086,650238,564May 19 10:33 AM
BIENAIME JEAN JACQUESChief Executive OfficerMay 17Sale91.735,000458,650233,564May 19 10:33 AM
Davis George EricEVP, General CounselMay 16Option Exercise14.391,14616,49185,301May 17 06:55 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 12Option Exercise17.335,00086,650243,496May 16 06:47 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 12Sale89.235,000446,150238,496May 16 06:47 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Option Exercise17.335,00086,650243,496May 09 01:19 PM
Mueller BrianSVP, Corporate ControllerMay 08Option Exercise21.512,60055,92616,068May 10 03:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Sale93.175,000465,850238,496May 09 01:19 PM
Mueller BrianSVP, Corporate ControllerMay 08Sale91.877,482687,33413,468May 10 03:23 PM
Davis George EricEVP, General CounselMay 05Option Exercise38.592,50096,47587,751May 09 01:21 PM
MEIER RICHARD ADirectorMay 05Option Exercise17.337,500129,97534,260May 09 01:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 05Option Exercise17.335,00086,650243,496May 09 01:19 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 05Option Exercise36.314,486162,87955,030May 09 01:23 PM
Davis George EricEVP, General CounselMay 05Sale100.342,500250,85385,251May 09 01:21 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 05Sale99.004,486444,11451,532May 09 01:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 05Sale99.005,000495,000238,496May 09 01:19 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 02Sale96.7430229,21551,532May 04 08:54 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 27Option Exercise17.335,00086,650243,194May 01 05:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 27Sale95.725,000478,600238,194May 01 05:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 25Option Exercise17.335,00086,650243,194Apr 27 06:49 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 25Sale94.005,000470,000238,194Apr 27 06:49 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 04Option Exercise14.393,00043,170238,194Apr 06 05:28 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 29Sale89.153,890346,79451,532Mar 31 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Option Exercise71.335,000356,650195,674Mar 17 06:27 PM
Davis George EricEVP, General CounselMar 16Sale91.962,238205,80673,729Mar 17 06:31 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 16Sale91.961,989182,90814,471Mar 17 06:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Sale91.965,000459,800190,674Mar 17 06:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Option Exercise17.335,00086,650211,364Mar 17 06:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Sale91.425,000457,100206,364Mar 17 06:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 13Option Exercise17.335,00086,650211,364Mar 15 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 13Sale92.685,000463,400206,364Mar 15 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 10Option Exercise17.335,00086,650211,364Mar 13 07:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 10Sale91.095,000455,450206,364Mar 13 07:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Option Exercise17.336,000103,980212,364Mar 13 07:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Sale90.186,000541,080206,364Mar 13 07:59 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 07Sale90.565,000452,80046,510Mar 08 07:31 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 06Sale93.322,303214,91620,761Mar 08 07:28 PM
Davis George EricEVP, General CounselMar 06Sale93.321,498139,79378,962Mar 08 07:24 PM
LAWLIS V BRYANDirectorMar 01Option Exercise17.337,500129,97521,360Mar 02 06:14 PM
LAWLIS V BRYANDirectorMar 01Sale95.007,500712,50013,860Mar 02 06:14 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 01Sale94.505,000472,50025,347Mar 02 06:20 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerFeb 28Option Exercise63.1030,0001,893,00060,347Mar 02 06:20 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerFeb 28Sale94.0030,0002,820,00030,347Mar 02 06:20 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 26Option Exercise17.335,00086,650175,682Jan 27 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 26Sale84.005,000420,000170,682Jan 27 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 25Option Exercise17.335,00086,650175,682Jan 27 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 25Sale84.445,000422,200170,682Jan 27 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 11Option Exercise17.334,00069,320174,682Jan 12 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 11Sale89.844,000359,360170,682Jan 12 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Option Exercise17.334,00069,320174,682Jan 12 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Sale91.314,000365,240170,682Jan 12 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 09Option Exercise17.334,00069,320174,682Jan 10 04:53 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJan 09Sale90.005,000450,00018,100Jan 10 04:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 09Sale89.794,000359,160170,682Jan 10 04:53 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 06Option Exercise17.334,00069,320174,682Jan 10 04:53 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 06Sale87.194,000348,760170,682Jan 10 04:53 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 30Option Exercise17.334,00069,320174,682Jan 03 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 30Sale83.354,000333,400170,682Jan 03 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 29Option Exercise17.334,00069,320174,682Jan 03 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 29Sale83.844,000335,360170,682Jan 03 05:46 PM
FUCHS HENRY JPresident, Worldwide R&DNov 25Option Exercise26.4915,000397,350128,878Nov 29 08:34 PM
FUCHS HENRY JPresident, Worldwide R&DNov 25Sale87.4015,0001,310,988113,878Nov 29 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 22Option Exercise26.4969,7431,847,492240,425Nov 23 04:42 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 22Sale85.6969,7435,976,515170,682Nov 23 04:42 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 21Option Exercise26.4969,7441,847,519240,426Nov 23 04:42 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 21Sale87.5669,7446,106,478170,682Nov 23 04:42 PM
Davis George EricEVP, General CounselNov 18Option Exercise38.595,000192,95075,798Nov 22 07:13 PM
Davis George EricEVP, General CounselNov 18Sale90.425,000452,10070,798Nov 22 07:13 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 16Option Exercise17.5441,670730,892365,038Nov 18 05:37 PM